Biomarin Pharmaceutical reported $3.82M in Interest Expense on Debt for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Interest Expense On Debt Change
Alexion Pharmaceuticals ALXN:US $ 27.1M 0.6M
Alnylam Pharmaceuticals ALNY:US $ 33.42M 901K
Amgen AMGN:US $ 281M 4M
Arena Pharmaceuticals ARNA:US $ 1.05M 0.02M
Biogen BIIB:US $ 66.3M 9.9M
Biomarin Pharmaceutical BMRN:US $ 3.82M 0.01M
Gilead Sciences GILD:US $ 256M 1M
Gw Pharmaceuticals GWPH:US $ 0.29M 0.02M
Insmed INSM:US $ 10.32M 2.76M
Intercept Pharmaceuticals ICPT:US $ 12.59M 0.17M
IONIS PHARMACEUT IONS:US $ 2.36M 0.06M
Moderna Inc MRNA:US 5M 2M
Neurocrine Biosciences NBIX:US $ 6.2M 0.2M
Ptc Therapeutics PTCT:US $ 22.56M 2.7M
Puma Biotechnology PBYI:US $ 3.52M 0.07M
Regeneron Pharmaceuticals REGN:US $ 14.4M 0.2M
Sarepta Therapeutics SRPT:US $ 15.83M 0.18M
United Therapeutics UTHR:US $ 4.7M 0.1M
Vertex Pharmaceuticals VRTX:US $ 15.48M 0.2M
YTE INCY:US $ 0.36M 0M